Keyword: CRISPR

A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.

Cancer drugmakers cut prices by 56.7% for China; Celltrion's Rituxan biosim wins FDA panel support; Otsuka renews digital pill deal with Proteus.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

After launching a vision-loss awareness effort last month, Allergan has teamed up with its first celebrity spokesman: Common.